Past HealthCare Headlines

2014

December 21, 2014
Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC

December 18, 2014
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma

December 18, 2014
Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies

December 16, 2014
TetraLogic Provides Update on Ovarian Cancer Study

December 8, 2014
Nicox expands Xailin™ range of ocular products

December 1, 2014
Trevena Announces Commencement of Public Offering

November 17, 2014
Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain

November 4, 2014
Promedior Receives Fast Track Designation for PRM-151 for the Treatment of Myelofibrosis

November 4, 2014
Proteostasis Therapeutics and Astellas Announce Collaboration for Therapies Modulating the Unfolded Protein Response

October 8, 2014
Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain

October 8, 2014
VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly

October 3, 2014
DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding

September 16, 2014
Vaxxas Initiates Research Project on Advancing Next Generation Technology for Polio Vaccine Delivery

September 16, 2014
Trevena Granted Key U.S. Composition of Matter Patent for TRV130

September 9, 2014
ReproCELL Acquires the iPS Cell Business Unit of Stemgent, Inc.

September 2, 2014
Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021

September 2, 2014
Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis

August 6, 2014
Trevena Initiates Phase 1 Multiple Ascending Dose Study of TRV734 for Acute and Chronic Pain

July 30, 2014
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec

July 30, 2014
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies

July 9, 2014
Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD")

July 8, 2014
GlobeImmune Announces Closing of Initial Public Offering

July 3, 2014
GlobeImmune Announces Pricing of Initial Public Offering

July 2, 2014
Nicox to acquire Aciex Therapeutics, Inc.

June 23, 2014
Trevena Announces Positive Phase 1 Results for TRV734 for Acute and Chronic Pain

June 13, 2014
New Seahorse Bioscience XFp Analyzer Makes Measuring Metabolism Affordable for Every Lab

June 11, 2014
Cardiovascular Systems Enrolls First Patient in Coast Study

June 6, 2014
cellnovo wins BIOVISION investor conference award

June 5, 2014
Radius Health, Inc. Announces Pricing of Initial Public Offering

June 4, 2014
Cardiovascular Systems Announces Coronary Data at Late-Breaker SCAI 2014 Scientific Sessions

June 2, 2014
HealthCare Pharmaceuticals Announces ASCO Presentation of DKN-01

May 30, 2014
Promedior to Present Positive Preliminary Phase 2 Data for PRM-151 in Myelofibrosis

May 28, 2014
Xencor Initiates Phase 1 Study of XmAb7195 for Asthma

May 22, 2014
PathoGenetix Technology Identifies Pathogenic E. coli and Listeria Bacteria for Food Safety Testing

May 16, 2014
PathoGenetix Protocol Enables Bacterial Identification from Clinical Samples

May 15, 2014
Xencor Presents Study Comparing XmAb7195 to Omalizumab

May 2, 2014
Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130

May 1, 2014
Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain

April 24, 2014
Theraclone Sciences Announces Identification of New Vulnerable Site on HIV Using Antibodies Discovered with Theraclone Technology

April 10, 2014
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb Antibody

April 7, 2014
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.

March 26, 2014
Marshfield Food Safety Shows Increased Accuracy in Salmonella Strain Typing with PathoGenetix RESOLUTION System

February 20, 2014
SENSEONICS RECEIVES ISO13485 CERTIFICATION

February 13, 2014
GlobeImmune Announces Completion of $7.5 Million Private Placement

February 6, 2014
PathoGenetix Delivers Bacterial Identification System to FDA for Evaluation

February 5, 2014
Trevena Announces Closing of Initial Public Offering

February 5, 2014
Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain

February 5, 2014
Cellnovo launches first Mobile Diabetes Management System

February 5, 2014
Physician Demand Continues to Build for Cardiovascular Systemsí New Coronary Artery Disease Treatment Technology

January 31, 2014
PathoGenetix Signs Sparton to Manufacture Bacterial Identification System

January 31, 2014
Trevena Increases Offering

January 30, 2014
Trevena Announces Pricing of its Initial Public Offering

January 28, 2014
VaxInnate Receives $2.1 million from New Jerseyís Technology Business Tax Certificate Transfer Program

January 21, 2014
TetraLogic Announces Licensing and Research Collaboration With Walter and Eliza Hall Institute of Medical Research

January 9, 2014
Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058)

January 9, 2014
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure

January 9, 2014
Radius Announces Key Changes to Management Team

January 8, 2014
Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis